Edaravon
 | |
| IUPAC ime | |
|---|---|
5-metil-2-fenil-2,4-dihidro-3H-pirazol-3-on | |
| Klinički podaci | |
| Način primene | Oralno |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| CAS broj | 89-25-8  |
| ATC kod | none |
| PubChem | CID 4021 |
| ChemSpider | 3881 |
| UNII | S798V6YJRP |
| KEGG | D01552 |
| ChEBI | CHEBI:31530 |
| ChEMBL | CHEMBL290916 |
| Sinonimi | MCI-186 |
| Hemijski podaci | |
| Formula | C10H10N2O |
| Molarna masa | 174,20 g/mol |
| |
| |
Edaravon (Radicut) je neuroprotektivni lek koji pomaže u neurološkom oporavku nakon akutne ishemije mozga i naknadne cerebralne infarkcije.[1] On deluje kao potentan antioksidans i jak sakupljaš slobodnih radikala, koji štiti od oksidativnog stresa i neuronalne apoptoze.[2][3][4] On je u prodaji u Japanu (od 2001)[1] i u Indiji.
Edaravon umanjuje dejstvo metamfetamina i 6-OHDA indukovanu dopaminergičku neurotoksičnost u strijatumu i substantia nigra, a nema efekta na metamfetaminom indukovano otpuštanje dopamina ili hipertermiju.[5][6] On takođe štiti protiv MPTP-posredovane dopaminergičke neurotoksičnosti u substantia nigra, mada ne i u strijatumu.[7][8][9]
Reference
- ^ а б Doherty, Annette M. (2002). Annual Reports in Medicinal Chemistry, Volume 37 (Annual Reports in Medicinal Chemistry). Boston: Academic Press. ISBN 978-0-12-040537-4.
- ^ Watanabe T, Tanaka M, Watanabe K, Takamatsu Y, Tobe A (2004). „[Research and development of the free radical scavenger edaravone as a neuroprotectant]”. Yakugaku Zasshi (на језику: Japanese). 124 (3): 99—111. PMID 15049127.
- ^ Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M (2006). „Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases”. Recent Patents on Cardiovascular Drug Discovery. 1 (1): 85—93. PMID 18221078.
- ^ Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006). „Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury”. CNS Drug Reviews. 12 (1): 9—20. PMID 16834755. doi:10.1111/j.1527-3458.2006.00009.x.
- ^ Yuan WJ; Yasuhara T; Shingo T; et al. (2008). „Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons”. BMC Neuroscience. 9: 75. PMC 2533664
. PMID 18671880. doi:10.1186/1471-2202-9-75.
- ^ Kawasaki T; Ishihara K; Ago Y; et al. (2006). „Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum”. European Journal of Pharmacology. 542 (1-3): 92—9. PMID 16784740. doi:10.1016/j.ejphar.2006.05.012.
- ^ Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T (2007). „Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum”. The Journal of Pharmacology and Experimental Therapeutics. 322 (1): 274—81. PMID 17429058. doi:10.1124/jpet.106.119206.
- ^ Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T (2008). „Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice”. Journal of Neural Transmission (Vienna, Austria : 1996). 115 (6): 831—42. PMID 18235988. doi:10.1007/s00702-008-0019-6.
- ^ Yokoyama H, Yano R, Aoki E, Kato H, Araki T (2008). „Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice”. Metabolic Brain Disease. 23 (3): 335—49. PMID 18648914. doi:10.1007/s11011-008-9096-3.
Literatura
- Doherty, Annette M. (2002). Annual Reports in Medicinal Chemistry, Volume 37 (Annual Reports in Medicinal Chemistry). Boston: Academic Press. ISBN 978-0-12-040537-4.
Spoljašnje veze
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
